Molecular Partners to Present at Upcoming Healthcare Investor Conference
Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN) has announced that CEO Patrick Amstutz, Ph.D., will participate in the SVB Leerink 11th Annual Global Healthcare Conference 2022. The presentation is scheduled for February 16, 2022, at 9:20 am ET. This clinical-stage biotech company specializes in developing DARPin therapeutics, a novel class of custom-built protein drugs aimed at addressing healthcare challenges. Their work spans infectious disease, oncology, and ophthalmology, with partnerships among leading pharmaceutical companies.
- None.
- None.
ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that its Chief Executive Officer, Patrick Amstutz, Ph.D., will participate in the SVB Leerink 11th Annual Global Healthcare Conference 2022. The presentation will take place on Wednesday, February 16, at 9:20 am ET.
The webcasted presentation will be made available on the Molecular Partners website.
About Molecular Partners AG
Molecular Partners AG is a clinical-stage biotech company developing DARPin therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics in the areas of infectious disease oncology, and ophthalmology, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas. www.molecularpartners.com; Find us on Twitter - @MolecularPrtnrs
FAQ
When will Molecular Partners AG present at the SVB Leerink Conference?
Who is the CEO of Molecular Partners AG?
What is the focus area of Molecular Partners AG?
What is the ticker symbol for Molecular Partners AG?
Where can I find the webcast of the Molecular Partners presentation?
